Trials / Active Not Recruiting
Active Not RecruitingNCT01868451
Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
A Pilot Study of Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma
- Status
- Active Not Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 118 (actual)
- Sponsor
- Memorial Sloan Kettering Cancer Center · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the outcomes across the 4 different treatment groups. The investigators hope that this treatment will improve the ability to cure more patients with HL and also limit the long-term side effects from the treatment. Although eliminating radiation in cohort 4 will eliminate the risk for long-term side effects from radiation, it is also possible that with BV+AVD chemotherapy alone there may be an increased risk of the Hodgkin lymphoma coming back after initial treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Brentuximab vedotin (SGN-35) | |
| DRUG | Doxorubicin HCL | |
| DRUG | Vinblastine Sulfate | |
| DRUG | Dacarbazine | |
| RADIATION | Involved-Site Radiation Therapy (ISRT) | |
| PROCEDURE | Interim PET | |
| RADIATION | consolidation volume RT (CVRT) |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2013-06-04
- Last updated
- 2025-07-09
Locations
10 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01868451. Inclusion in this directory is not an endorsement.